Jump To Jump To Watch View Summit Archive BiTE Technology in Immuno-Oncology March 4, 2021 Doctor Michael Groaning of Amgen discusses a new, groundbreaking immuno-oncology platform - Bispecific T-cell engager technology, or BiTE.This session was part of our VIRTUAL ZERO Prostate Cancer Summit, a free online event that took place from February 28 to March 4, 2021.Watch Summit Session Archives At each ZERO Summit, you'll experience the Bold for Blue Awards, educational sessions, advocacy training, and more. See the video archives to find more of what you can expect to see when you join us at this year’s Summit! View Summit Archive Clinical Trials Research Treatment Options Videos & Webinars ZERO Prostate Cancer Summit Contributors Michael Groaning, PhD, Prostate Cancer Global Medical Affairs Lead Dr. Groaning attended Colorado State University until 2000 when he moved to Zurich, Switzerland for his post-doctoral studies at the Swiss Federal Institute of Technology (ETH). Dr. Groaning started his career in the pharmaceutical industry at F. Hoffmann – La Roche in Basel, Switzerland in their Discovery Chemistry group before transferring to Boulder, Colorado as a process research chemist where he optimized the production of a key intermediate for Tamiflu. Shelby Moneer, Vice President, Patient Programs & Education Shelby Moneer was the Vice President of Patient Programs & Education at ZERO Prostate Cancer until April 2025. More for you
Doctor Michael Groaning of Amgen discusses a new, groundbreaking immuno-oncology platform - Bispecific T-cell engager technology, or BiTE.This session was part of our VIRTUAL ZERO Prostate Cancer Summit, a free online event that took place from February 28 to March 4, 2021.Watch
Summit Session Archives At each ZERO Summit, you'll experience the Bold for Blue Awards, educational sessions, advocacy training, and more. See the video archives to find more of what you can expect to see when you join us at this year’s Summit! View Summit Archive
